Protective effect of silymarin in streptozotocin-induced diabetic dyslipidaemia in rats

Manju Sharma1*, K. K. Pillai1, Tarique Anwer1, Abul Kalam Najmi1, Syed Ehtaishamul Haque1 and Yasmin Sultana2

1Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard, (Hamdard University), New Delhi-110 062, India; 2Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, (Hamdard University), New Delhi-110 062, India

Received for publication March 18, 2009; accepted July 23, 2010

SUMMARY

The present study investigated the effect of silymarin, a flavonoid, on streptozotocin (STZ) - induced diabetic dyslipidaemia in rats. Experimental diabetes was induced by a single intraperitoneal injection of STZ (60 mg/kg). Silymarin (25 mg/kg and 50 mg/kg) was orally administered to diabetic rats for a period of 15 days. Blood glucose levels, serum lipid profile and liver glycogen levels were estimated following the established procedures. Biochemical observations were supplemented with histological examination of liver sections. Oral administration of silymarin to diabetic rats significantly (P < 0.001) decreased the blood glucose levels (259.99 ± 23.64 vs. 99.90 ± 2.62 [25 mg] & 89.17 ± 3.32 [50 mg]). The most interesting finding was the significant (p < 0.001) increase in HDL-cholesterol levels (26.99 ± 0.61 vs. 40.55 ± 0.52 [25 mg] & 41.12 ± 0.37 [50 mg]) whereas, there was a significant decrease in serum total cholesterol (TCh), triglycerides (TG), low density lipoprotein (LDL) and very low density lipoprotein (VLDL) cholesterol levels observed in silymarin treated diabetic rats. STZ treatment caused significant degeneration of liver parenchyma, which was normalized to near normal morphology by administration of silymarin. The findings indicate that silymarin effectively improved the overall lipid profile and restored the glycogen stores in the liver of STZ-induced diabetic rats, in a dose dependent manner. The results indicate existence of abnormalities in lipid metabolism in STZ-induced diabetic rats and suggest a protective effect of silymarin in this animal model.

Key words: Diabetes mellitus; Silymarin; Streptozotocin; Dyslipidaemia; Liver glycogen

INTRODUCTION

Diabetes mellitus produces lipid abnormalities, which is the main risk factor for coronary heart disease (CHD) (Stamler et al., 1993; Haffner, 1999).

In both types of diabetes, abnormalities of lipid metabolism are important, but the nature of these abnormalities is different and the therapeutic approach also differs. Elevated triglyceride (TG) level, reduced high density lipoprotein (HDL) cholesterol and a preponderance of small, dense low density lipoprotein (LDL) particles are the key abnormalities that constitute diabetic dyslipidaemia (Barrett-Connor et al., 1982). Poor glycemic control exaggerates these abnormalities (Adeneye et al.,...
Early detection and treatment of elevated cholesterol levels is likely to be of benefit in these patients (Pyolara et al., 1997). The management of dyslipidaemia, a well recognized and modifiable risk factor among patients with DM, is an important element in the multifactorial approach to prevent CVD (Schwartz, 2006). Any therapy that improves glycaemic control will improve diabetic dyslipidaemia. Thus treatment with insulin, sulfonylurea, metformin, acarbose and rosiglitazone has all been reported to improve lipid profile (Best and Neal, 2000).

Many plant extracts and some compounds purified from them have been reported to decrease blood glucose and reverse above mentioned abnormalities (Shukla et al., 2000). Purified orally active compounds from fenugreek seeds, banyan tree bark, bitter gourd fruits and garlic bulbs have been extensively investigated in several Indian laboratories for their beneficial effect in diabetes hypercholesterolemia (Shukla et al., 2004; Sathishekar and Subramanian, 2005). Silymarin is a flavonoid extracted from *Silybum marianum* L. (milk thistle) that grows in Europe and some parts of Asia including India. Silymarin contains 50 - 70% of flavolignans (silybin, silychristin, silydianin and isosilybin as the major constituents (Muriel et al., 1992). Chemically the drug is 7, 8-dihydroxyflavone. It is commonly used as a hepatoprotective agent. It is a free radical scavenger and a membrane stabilizer that prevents lipid peroxidation and its associated cell damage in some experimental models (Muriel and Mourelle, 1990; Faya et al., 1993). Silymarin has also been shown to prevent the damage induced by oxidative agents in hepatic membranes (Greimel and Koch, 1977), microsomes and mitochondria (Bindoli et al., 1977). Furthermore, silybin is reported to protect the exocrine pancreas from cyclosporin A toxicity (Schenfeld et al., 1997). Beneficial effect of silymarin in improving the glycaemic profile in type 2 diabetic patients has also been reported (Huseini et al., 2006). Silymarin, due to its antioxidant action has been found to be protective in alloxan induced diabetes (Soto et al., 1998, Soto et al., 2003) and anthracycline induced toxicity (Chlopeikova et al., 2004). Recently we have demonstrated that silymarin provides protection against STZ-induced lipid peroxidation and β cell damage in rat pancreas possibly by inhibiting lipid peroxidation and scavenging the free radicals (Sharma et al., 2008). These findings support the notion that possibly due to its antioxidant and membrane stabilizing properties silymarin is known to protect different organs and cells. However, the effect of silymarin on STZ-induced diabetic dyslipidaemia has not yet been studied. We therefore further investigated the effect of silymarin on STZ-induced diabetic dyslipidaemia in rats.

**MATERIALS AND METHODS**

**Animals**

Wistar rats weighing (150 - 200 g) were used for this study. They were kept in the animal house (Faculty of Pharmacy, Jamia Hamdard, New Delhi, India) for one week for proper acclimatization before starting the experiment under controlled condition of illumination (12 h light/12 h darkness) and temperature 20 – 25°C. They were housed under ideal laboratory conditions, maintained on standard pellet diet (Lipton rat feed, Ltd; Pune) and water *ad libitum* throughout the experimental period. The experimental study was approved by the Institutional Animal Ethics Committee of Jamia Hamdard, New Delhi.

**Drugs and chemicals**

STZ was purchased from the Sigma Chemical Co. (USA). Silymarin (Silybon) was obtained from Microlabs Ltd., India. Glucose, cholesterol and triglycerides kits were procured from Span diagnostics, Surat, India. All the other chemicals used were of analytical grade.

**Induction of diabetes**

STZ in citrate buffer (pH - 4.5) was administered intraperitoneally (i.p.) at a single dose of 60 mg/kg
to groups II, III and IV. Three days after STZ treatment, development of diabetes was confirmed by measuring blood glucose level. Rats with blood glucose level of 200 mg/dl or higher were considered to be diabetic. Silymarin (25 and 50 mg/kg, p.o.) was given to STZ-diabetic rats for 15 days to group III and IV animals.

**Experimental design**

The rats were divided into four groups containing six animals in each group and received the following treatment.

- Group I: Normal control rats, received normal saline (1 ml/kg, p.o.) for 15 days
- Group II: Diabetic control rats, received STZ in a single dose (60 mg/kg, i.p.)
- Group III: Diabetic treated rats, received silymarin (25 mg/kg, p.o.) for 15 days
- Group IV: Diabetic treated rats, received silymarin (50 mg/kg, p.o.) for 15 days

**Biochemical estimations**

On the last day of experiment, blood samples were collected for biochemical estimations. Later the animals were sacrificed and livers were removed, cleaned and washed in ice-cold normal saline for biochemical and histological study. Blood glucose was determined by glucose oxidase method (Braham and Trinder, 1972) using a commercial diagnostic kit from Span diagnostics Ltd, Surat, India. Serum was separated for assessment of lipid profile i.e. serum total cholesterol (Wybenga et al., 1970), Serum triglycerides (Bucolo and David, 1973) and HDL-cholesterol (Warnick et al., 1985) were estimated using diagnostic kits of Span Diagnostics, Surat, India. LDL and VLDL-cholesterol levels were calculated by the method of Friedwald et al., (1972). The liver glycogen content was determined using the method of Montgomery (1957). The liver was isolated immediately after sacrificing the animal and washed with ice-cold saline. It was then fixed in 10% neutral buffered formalin solution. Sections of 3-5 µm thickness were stained with hematoxylin and eosin (H.E.) for histopathological examination.

**Statistical analysis**

Data were expressed as the mean ± standard error (S.E) of the means. For a statistical analysis of the data, group means were compared by one-way analysis of variance (ANOVA) with post hoc analysis.

**Fig. 1.** Effect of silymarin on blood glucose level in STZ-induced diabetic rats. The data are expressed in mean ± S.E. (n = 6). *P < 0.001 compared with the corresponding value for normal control group (group I). **P < 0.001 compared with diabetic control animals (group II).
The Tukey-Kramer test post hoc was applied to identify significance among groups. \( P < 0.05 \) was considered to be statistically significant.

**RESULTS**

Fig. 1. shows the effect of silymarin on blood glucose level. Significant \( (P < 0.001) \) increase in the blood glucose level was observed in animals treated with STZ when compared with normal control rats. Oral administration of silymarin at two doses (25 mg/kg and 50 mg/kg) reduced the blood glucose level significantly \( (P < 0.001) \).

Table 1 shows the effect of silymarin on the serum lipid profile. A significant increase \( (P < 0.001) \) in TCh, TG, LDL and VLDL-cholesterol levels were observed in STZ diabetic rats. Administration of silymarin at the doses of 25 mg/kg and 50 mg/kg significantly \( (P < 0.001) \) reduced the elevated levels of these cholesterols and triglycerides when compared with diabetic control rats. Diabetic animals treated with silymarin (50 mg/kg) had better effect in respect to the reduction in the level of serum cholesterol and triglycerides. The HDL-cholesterol level was decreased significantly \( (P < 0.001) \) in STZ diabetic rats when compared with normal control rats. Co-administration with silymarin in two doses increased the HDL-cholesterol level significantly \( (P < 0.001) \). Diabetic rats treated with silymarin (50 mg/kg) had almost same level of HDL cholesterol as of normoglycemic animals.

Effect of silymarin on liver glycogen content of different groups is shown in Fig. 2. Liver glycogen content was reduced significantly \( (P < 0.001) \) in STZ-diabetic rats when compared with normal control rats. It was further observed that diabetic rats treated with silymarin (25 and 50 mg/kg) showed a significant \( (P < 0.05 – P < 0.01) \) replenishment of glycogen stores in the liver. However, the levels of glycogen build up had not touched those observed in normal control rats.

Fig. 3A showed a section of rat liver from normal control group revealing normal hepatocytes and well brought out portal triad comprising hepatic artery, bile duct and portal vein. STZ administration induced severe degeneration of liver parenchyma and occasional focal necrosis with lymphocytic infiltration (Fig. 3B). Silymarin (25 mg/kg) treated rat liver showed normal portal triad comprising hepatic artery, bile duct and portal vein. Hepatocytes were found to be perfectly normal (Fig. 3C).

| Table 1. Effect of silymarin on serum lipid profile (Total Cholesterol, HDL cholesterol, Triglycerides, VLDL Cholesterol and LDL Cholesterol) in streptozotocin-induced diabetic rats |
|-----------------|----------------|----------------|----------------|----------------|----------------|
| Groups          | Treatment                  | TCh (mg/dl) | HDL (mg/dl) | TG (mg/dl) | VLDL (mg/dl) | LDL (mg/dl) |
| I               | Normal control             | 81.53 ± 1.18 | 41.37 ± 0.89 | 75.53 ± 1.53 | 15.10 ± 0.30 | 25.05 ± 1.61 |
| II              | STZ (60 mg/kg, i.p)        | 119.43 ± 3.44a | 26.99 ± 0.61a | 135.10 ± 1.37a | 27.02 ± 0.27a | 65.43 ± 3.39a |
| III             | STZ+Silymarin (25 mg/kg)   | 87.75 ± 0.50b | 40.55 ± 0.52b | 95.73 ± 1.55b | 19.15 ± 0.30b | 28.04 ± 0.78b |
| IV              | STZ+Silymarin (30 mg/kg)   | 80.73 ± 1.10b | 41.12 ± 0.37b | 83.86 ± 0.62b | 16.77 ± 0.12b | 22.83 ± 1.13b |

The data are expressed in mean ± SEM; n = 6 in each group. \( ^aP < 0.001 \) compared with the corresponding value for normal control group (group I). \( ^bP < 0.001 \) compared with the corresponding value of diabetic control animals (group II).
Silymarin (50 mg/kg) treatment remarkably reversed the damage of hepatic cells caused by STZ as evidenced by normal portal triad (Fig. 3D) and all the hepatocytes surrounding the portal triad are well preserved without any abnormality thereby revealing the well protective effect of silymarin.

**DISCUSSION**

Cardiovascular complication is the primary cause of mortality in diabetes mellitus (Alzahrani et al., 2003). The long-term complications of diabetes are of great concern, but cardiovascular complication is particularly serious. This accounts for much premature morbidity and mortality and is responsible for about 80% deaths among patients with type 2 diabetes (Barnett, 2001). For this reason, health professionals are emphasizing the importance of managing not just glycaemia, but also other cardiovascular risk factors including obesity, dyslipidaemia and hypertension. Dyslipidaemia, which may include raised total cholesterol and LDL-cholesterol, low HDL and raised triglycerides is seen in well over a third of people with diabetes and was observed in our study on STZ-diabetic rats. High level of total cholesterol is one of the major factors for coronary heart diseases and it is well known that hyperlipidaemia and the incidence of atherosclerosis is increased in diabetes (Tan et al., 2005). The liver and some other tissues participate in the uptake, oxidation and metabolic conversion of free fatty acids, synthesis of cholesterol and phospholipids and secretion of specific classes of plasma lipoprotein. Lowering of serum lipid levels through dietary or drug therapy seems to be associated with a decrease in the risk of vascular disease and related complications (Betteridge, 1997).

The effect of flavonoids and flavonoid rich extracts on reducing lipid levels effectively has been reported in several studies (Valsa et al., 1995; Anila and Vijayalakshmi, 2002). Silymarin, a flavonolignan has been widely used from ancient times to treat liver disorders, including acute and chronic viral hepatitis, toxin/drug-induced hepatitis and cirrhosis/alcoholic liver diseases. It has also been reported to be effective in certain cancers (Dixit et al., 2007).

In our previous study we have shown that silymarin protects STZ-induced lipid peroxidation and β-cell damage in rat pancreas (Sharma et al., 2008). The reduction in lipoperoxidative damage by silymarin resulted in a significant decrease in blood glucose levels. In the present study when silymarin was given to diabetic rats, the serum total cholesterol, LDL-cholesterol, VLDL-cholesterol and triglycerides levels were significantly reduced, in
addition to a reduction of blood glucose level. We observed an increase in HDL-cholesterol levels in silymarin treated group. This finding is in favour of silymarin, since low HDL-cholesterol levels are considered as a risk for coronary heart disease. HDL is strongly protective against atherosclerosis. An important mechanism underlying this protective effect is the role of HDL in the removal of excess cholesterol from the peripheral tissues. But in addition, HDL also protects by inhibiting lipoprotein role for oxidation of lipoproteins such as LDL in the pathogenesis of atherosclerosis (Steinberg et al., 1989; Witztum and Steinberg, 1991). The antioxidant properties of HDL are due to in part to serum paraoxonase, an esterase carried on HDL that can degrade certain biologically active oxidized phospholipids (Hegele, 1999; Shih et al., 2000). Over the past decade, a number of promising new targets have been identified that presents exciting new opportunities for treatment of low HDL levels. It has also become clear that HDL is functionally very heterogeneous (Navab et al., 1996). Thus, rather than attempting to increase levels of HDL, it may be more productive to focus on functional properties such as its antioxidant activity. Silymarin itself an antioxidant was found to improve the HDL levels in diabetic rats.

The liver glycogen content was reduced significantly as compared to normal control rats, substantiating depletion of liver glycogen and failure of utilization by hepatocytes in STZ-diabetic rats. The increase in the content of liver glycogen in STZ diabetic rats treated with silymarin revealed its capacity to regenerate the liver cells. This can be explained by improvement in liver cell metabolism following antioxidant therapy. This compound has shown protective effects against several models of hepatotoxicity (Mourelle et al., 1989; Muriel and Mourelle, 1990; Paya et al., 1993) and has been used medicinally for centuries as herbal medicine for the treatment of liver related disorders. This might in turn contribute to the regulation of plasma glucose. Some recent studies have shown a direct cytoprotective effect of silymarin in pancreatic beta cell (Matsuda et al., 2005). The necrotic and infiltrative changes of liver, which were consistently observed in animals treated with STZ, were reduced to a minimum with silymarin treatment, further substantiating the protective effect of silymarin in the liver. These results suggest that silymarin may be therapeutically beneficial for the treatment of diabetes and related disorders.

In summary, the present study demonstrates the protective effect of silymarin by improving lipid profile, restoring the glycogen content and preventing liver damage in STZ-induced diabetic rats. Therefore, treatment with silymarin can be beneficial in maintaining a better metabolic compensation of glucose metabolism in diabetic patients with dyslipidaemia and liver disorder.

REFERENCES


Best J D and O’Neal DN. Diabetic Dyslipidaemia: Current treatment recommendations, Drugs 59, 1101-1110.


Braham D, Trinder P. (1972) An improved colour reaction for the determination of blood glucose by
Silymarin in diabetic dyslipidaemia


